What is Avalo Therapeutics's cash ratio?

Avalo Therapeutics (AVTX) reported cash ratio of 2.2× in Q1 2026.

How has Avalo Therapeutics's cash ratio changed year-over-year?

Avalo Therapeutics's cash ratio decreased by 90.2% year-over-year, from 22.3× to 2.2×.

What is the long-term trend for Avalo Therapeutics's cash ratio?

Over 5 years (2020 to 2025), Avalo Therapeutics's cash ratio has grown at a -0.2% compound annual growth rate (CAGR), from 1.3× to 1.2×.

What does cash ratio mean?

Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.

Avalo Therapeutics AVTX Cash ratio

Cash ratio at other companies

Eli LillyLLY

0.1×0.0×

AbbVieABBV

0.2×+0.1×

XencorXNCR

0.2×-0.3×

AbCellera Biologics Inc.ABCL

2.2×-0.3×

AnaptysBio, Inc.ANAB

6×+3.7×

Absci CorporationABSI

0.5×-1.9×

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,800%

Enterprise value$929.6M-1,353%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Calculated from Avalo Therapeutics’s reported figures.

cash and equivalents/total current liabilities=2.2×

Based on the most recent quarter.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's cash ratio?: Avalo Therapeutics (AVTX) reported cash ratio of 2.2× in Q1 2026.
How has Avalo Therapeutics's cash ratio changed year-over-year?: Avalo Therapeutics's cash ratio decreased by 90.2% year-over-year, from 22.3× to 2.2×.
What is the long-term trend for Avalo Therapeutics's cash ratio?: Over 5 years (2020 to 2025), Avalo Therapeutics's cash ratio has grown at a -0.2% compound annual growth rate (CAGR), from 1.3× to 1.2×.
What does cash ratio mean?: Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.